期刊文献+

非小细胞肺癌患者血清CYFRA21-1、VEGF及CEA的表达及与临床病理特征的相关性研究 被引量:24

Non-Small Cell Lung Cancer: Expression of Serum CYFRA21-1,VEGF and CEA and Their Correlation with Clinicopathological Features
原文传递
导出
摘要 目的:研究非小细胞肺癌(NSCLC)患者血清细胞角蛋白19片段(CYFRA21-1)、血管内皮生长因子(VEGF)、癌胚抗原(CEA)的表达及与临床病理特征的相关性。方法:选取2015年12月至2016年4月在我院接受治疗的NSCLC患者120例作为观察组,另选取同期在我院接受治疗的肺部良性病变患者50例作为良性对照组,比较两组患者血清中CYFRA21-1、VEGF及CEA的表达,分析观察组患者血清中CYFRA21-1、VEGF及CEA的表达与临床病理特征之间的关系,采用Pearson相关系数分析观察组患者血清中CYFRA21-1、VEGF、CEA的相关性。结果:观察组患者血清中的CYFRA21-1、VEGF及CEA水平均高于良性对照组(P<0.05)。鳞状细胞癌患者血清中CYFRA21-1水平高于腺癌患者,CEA水平低于腺癌患者(P<0.05),鳞状细胞癌患者和腺癌患者血清中VEGF水平比较无统计学差异(P>0.05)。TNM分期为III-IV期的观察组患者血清中CYFRA21-1、VEGF及CEA水平均明显高于I-II期患者,有统计学差异(P<0.05)。经Pearson相关系数分析显示,观察组患者血清中CYFRA21-1与VEGF、CEA呈正相关(r=0.512,0.423,P=0.000,0.000),VEGF与CEA呈正相关(r=0.452,P=0.000)。结论:NSCLC患者血清中CYFRA21-1、VEGF及CEA呈高表达,且CYFRA21-1、CEA与病理类型和TNM分期有关,VEGF与TNM分期有关,且三种指标存在一定的相关性。 Objective: To investigate the expression ofcytokeratin fragment 19 (CYFRA21-1),vascular endothelial growth factor (VEGF) and carcinoembryonic antigen (CEA) in patients with non-small cell lung cancer (NSCLC) and its correlation with clinicopathological characteristics. Methods: A total of 120 cases of NSCLC, who were treated in the First People's Hospital of Qinzhou from December 2015 to April 2016, were selected as observation group, and 50 patients with benign pulmonary lesions in this hospital during the same period were selected as benign control group. The expressions of CYFRA21-1,VEGF and CEA in the two groups were compared. The relationship between the expression of serum CYFRA21-1, VEGF and CEA and the clinicopathological characteristics of NSCLC patients were analyzed. Pearson correlation coefficient was used to analyze the correlation of CYFRA21-1, VEGF and NSCLC in the serum of NSCLC patients. Results: The levels of CYFRA21-1, VEGF and CEA in the serum of the observation group were higher than those in the benign control group (P〈0.05). The serum level of CYFRA21-1 in the patients with squamous cell carcinoma was higher than that in the patients with adenocarcinoma, the level of CEA in the patients with squamous cell carcinoma was lower than that in the patients with adenocarcinoma (F〈0.05). There was no significant difference in serum VEGF level between patients with squamous cell carcinoma and adenocarcinoma (P〉0.05). The levels of CYFRA21-1,VEGF and CEA in the serum of NSCLC patients with stage Ⅲ-Ⅳ of TNM stage were significantly higher than those in stage Ⅰ-Ⅱ, there were statistically significant differences (P〈0.05). Pearson correlation coefficient analysis showed that CYFRA21-1 in the serum of the observation group was positively correlated with VEGF and CEA (r=0.512, 0.423, P=0.000,0.000), VEGF was positively correlated with CEA (r=0.452, P=0,000). Conclusion: CYFRA21-1, VEGF and CEA in the serum of NSCLC patients are highly expressed, and CYFRA21-1 and CEA are related to pathological type and TNM stage, VEGF is related to TNM stage,and there is a certain correlation among the three indicators.
作者 黄丽珍 车建华 段相会 李苗 黄永龙 HUANG Li-zhen;CHE Jian-hua;DUAN Xiang-hui;LI Miao;HUANG Yong-long(Department of Medical Oncology, The First People's Hospital of Qinzhou, Qinzhou, Guangxi, 535000, Chin)
出处 《现代生物医学进展》 CAS 2018年第7期1344-1347,共4页 Progress in Modern Biomedicine
基金 广西壮族自治区卫生和计划生育委员会自筹经费科研项目(Z20170968)
关键词 非小细胞肺癌 细胞角蛋白19片段 血管内皮生长因子 癌胚抗原 病理特征 相关性 Non-small cell lung cancer Cytokeratin fragment 19 Vascular endothelial growth factor Cancer embryo resistance Pathological features Correlation
  • 相关文献

参考文献6

二级参考文献44

  • 1王金万,孙燕,刘永煜,于起涛,张沂平,李凯,朱允中,周清华,侯梅,管忠震,李维廉,庄武,王东林,梁后杰,秦凤展,卢辉山,刘晓晴,孙红,张燕军,王杰军,罗素霞,杨瑞合,涂远荣,王秀问,宋恕平,周静敏,游丽芬,王竞,姚晨.重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究[J].中国肺癌杂志,2005,8(4):283-290. 被引量:625
  • 2Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002[J]. CA Cancer J Clin, 2005, 55(2) : 74-108.
  • 3Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010[J]. CA Cancer J Clin, 2010, 60(5) : 277-300.
  • 4Green MR. Targeting targeted therapy[J]. N Engl J Med, 2004, 350(21) : 2191-2193.
  • 5MassareUi E, Andre F, Liu DD, et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small- cell lung eancer[J]. Lung Cancer, 2003, 39(1 ) : 55-61.
  • 6Xue C, Hu Z, Jiang W, et al. National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China [J]. Lung Cancer, 2012, 77(2) : 371-375.
  • 7Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy [ J ]. Science, 2004, 304(5676) : 1497-1500.
  • 8Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib[ J]. N Engl J Med, 2004, 350(21 ) : 2129-2139.
  • 9Pao W, Ladanyi M. Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method [ J]. Clin Cancer Res, 2007, 13(17): 4954-4955.
  • 10Ogino S, Kawasaki T, Brahmandam M, et al. Sensitive Sequencing Method for < i > KRAS </i > Mutation Detection by Pyrosequencing[J]. J Mol Diagn, 2005, 7(3) : 413-421.

共引文献520

同被引文献263

引证文献24

二级引证文献95

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部